Kirsten Bibbins-Domingo1, David C Grossman2, Susan J Curry3, Michael J Barry4, Karina W Davidson5, Chyke A Doubeni6, John W Epling7, Alex R Kemper8, Alex H Krist9,10, Ann E Kurth11, C Seth Landefeld12, Carol M Mangione13, William R Phillips14, Maureen G Phipps15, Michael Silverstein16, Melissa A Simon17, Chien-Wen Tseng18,19. 1. University of California, San Francisco. 2. Kaiser Permanente Washington Health Research Institute, Seattle. 3. University of Iowa, Iowa City. 4. Harvard Medical School, Boston, Massachusetts. 5. Columbia University, New York, New York. 6. University of Pennsylvania, Philadelphia. 7. Virginia Tech Carilion School of Medicine, Roanoke. 8. Duke University, Durham, North Carolina. 9. Fairfax Family Practice Residency, Fairfax, Virginia. 10. Virginia Commonwealth University, Richmond. 11. Yale University, New Haven, Connecticut. 12. University of Alabama at Birmingham. 13. University of California, Los Angeles. 14. University of Washington, Seattle. 15. Brown University, Providence, Rhode Island. 16. Boston University, Boston, Massachusetts. 17. Northwestern University, Evanston, Illinois. 18. University of Hawaii, Honolulu. 19. Pacific Health Research and Education Institute, Honolulu, Hawaii.
Abstract
IMPORTANCE: Preeclampsia affects approximately 4% of pregnancies in the United States. It is the second leading cause of maternal mortality worldwide and may lead to serious maternal complications, including stroke, eclampsia, and organ failure. Adverse perinatal outcomes for the fetus and newborn include intrauterine growth restriction, low birth weight, and stillbirth. Many of the complications associated with preeclampsia lead to early induction of labor or cesarean delivery and subsequent preterm birth. SUBPOPULATION CONSIDERATIONS: Preeclampsia is more prevalent among African American women than among white women. Differences in prevalence may be, in part, due to African American women being disproportionally affected by risk factors for preeclampsia. African American women also have case fatality rates related to preeclampsia 3 times higher than rates among white women. Inequalities in access to adequate prenatal care may contribute to poor outcomes associated with preeclampsia in African American women. OBJECTIVE: To update the 1996 US Preventive Services Task Force (USPSTF) recommendation on screening for preeclampsia. EVIDENCE REVIEW: The USPSTF reviewed the evidence on the accuracy of screening and diagnostic tests for preeclampsia, the potential benefits and harms of screening for preeclampsia, the effectiveness of risk prediction tools, and the benefits and harms of treatment of screen-detected preeclampsia. FINDINGS: Given the evidence that treatment can reduce maternal and perinatal morbidity and mortality, and the well-established accuracy of blood pressure measurements, the USPSTF found adequate evidence that screening for preeclampsia results in a substantial benefit for the mother and infant. In addition, there is adequate evidence to bound the harms of screening for and treatment of preeclampsia as no greater than small. Therefore, the USPSTF concludes with moderate certainty that there is a substantial net benefit of screening for preeclampsia in pregnant women. CONCLUSIONS AND RECOMMENDATION: The USPSTF recommends screening for preeclampsia in pregnant women with blood pressure measurements throughout pregnancy. (B recommendation).
IMPORTANCE: Preeclampsia affects approximately 4% of pregnancies in the United States. It is the second leading cause of maternal mortality worldwide and may lead to serious maternal complications, including stroke, eclampsia, and organ failure. Adverse perinatal outcomes for the fetus and newborn include intrauterine growth restriction, low birth weight, and stillbirth. Many of the complications associated with preeclampsia lead to early induction of labor or cesarean delivery and subsequent preterm birth. SUBPOPULATION CONSIDERATIONS: Preeclampsia is more prevalent among African American women than among white women. Differences in prevalence may be, in part, due to African American women being disproportionally affected by risk factors for preeclampsia. African American women also have case fatality rates related to preeclampsia 3 times higher than rates among white women. Inequalities in access to adequate prenatal care may contribute to poor outcomes associated with preeclampsia in African American women. OBJECTIVE: To update the 1996 US Preventive Services Task Force (USPSTF) recommendation on screening for preeclampsia. EVIDENCE REVIEW: The USPSTF reviewed the evidence on the accuracy of screening and diagnostic tests for preeclampsia, the potential benefits and harms of screening for preeclampsia, the effectiveness of risk prediction tools, and the benefits and harms of treatment of screen-detected preeclampsia. FINDINGS: Given the evidence that treatment can reduce maternal and perinatal morbidity and mortality, and the well-established accuracy of blood pressure measurements, the USPSTF found adequate evidence that screening for preeclampsia results in a substantial benefit for the mother and infant. In addition, there is adequate evidence to bound the harms of screening for and treatment of preeclampsia as no greater than small. Therefore, the USPSTF concludes with moderate certainty that there is a substantial net benefit of screening for preeclampsia in pregnant women. CONCLUSIONS AND RECOMMENDATION: The USPSTF recommends screening for preeclampsia in pregnant women with blood pressure measurements throughout pregnancy. (B recommendation).
Authors: Natasa M Milic; Elisabeth Codsi; Yvonne S Butler Tobah; Wendy M White; Andrea G Kattah; Tracey L Weissgerber; Mie Saiki; Santosh Parashuram; Lisa E Vaughan; Amy L Weaver; Marko Savic; Michelle M Mielke; Vesna D Garovic Journal: Mayo Clin Proc Date: 2018-12 Impact factor: 7.616
Authors: Liona C Poon; Andrew Shennan; Jonathan A Hyett; Anil Kapur; Eran Hadar; Hema Divakar; Fionnuala McAuliffe; Fabricio da Silva Costa; Peter von Dadelszen; Harold David McIntyre; Anne B Kihara; Gian Carlo Di Renzo; Roberto Romero; Mary D'Alton; Vincenzo Berghella; Kypros H Nicolaides; Moshe Hod Journal: Int J Gynaecol Obstet Date: 2019-05 Impact factor: 3.561
Authors: Karen Curtin; Lauren H Theilen; Alison Fraser; Ken R Smith; Michael W Varner; Gregory S Hageman Journal: Hypertens Pregnancy Date: 2019-04-12 Impact factor: 2.108
Authors: Vesna D Garovic; Wendy M White; Lisa Vaughan; Mie Saiki; Santosh Parashuram; Oscar Garcia-Valencia; Tracey L Weissgerber; Natasa Milic; Amy Weaver; Michelle M Mielke Journal: J Am Coll Cardiol Date: 2020-05-12 Impact factor: 24.094
Authors: Natalie A Bello; Jonathan J Woolley; Kirsten Lawrence Cleary; Louise Falzon; Bruce S Alpert; Suzanne Oparil; Gary Cutter; Ronald Wapner; Paul Muntner; Alan T Tita; Daichi Shimbo Journal: Hypertension Date: 2017-12-11 Impact factor: 10.190